arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ClearPoint Neuro, Inc.

CLPT
$8.68 ▼ -1.48 (-14.62%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ClearPoint Neuro, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $245.8M
Dividend Yield —
Revenue Growth 17.8% ↘
Op. Margin -65.4% ↘
ROIC -31.4% ↗
FCF / Share $-0.86 ↘
Trailing P/E —
Price / Book 9.1x
FCF Yield —
Debt / Equity 1.75
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$36.97M
↑ +17.8% —
Net Income Profit after all expenses
$-25.54M
↓ -35.0% —
Operating Margin Operating profit as % of sales
-65.4%
↓ -4.0% 4th
FCF / Share Free cash flow per share
$-0.86
↓ -153.0% —
Long-Term Debt Long-term obligations
$49.08M
↑ +393.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns ↓
10
Financial Health →
18
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 66 quarters